Get the Stockscreener App
254.95
3.18%
7.86
After Hours:
254.95
Krystal Biotech Inc stock is traded at $254.95, with a volume of 240.46K.
It is up +3.18% in the last 24 hours and down -6.44% over the past month.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
See More
Previous Close:
$247.09
Open:
$251.04
24h Volume:
240.46K
Relative Volume:
0.83
Market Cap:
$7.45B
Revenue:
$389.13M
Net Income/Loss:
$204.83M
P/E Ratio:
37.25
EPS:
6.8443
Net Cash Flow:
$188.91M
1W Performance:
+1.64%
1M Performance:
-6.44%
6M Performance:
+58.21%
1Y Performance:
+32.58%
1-Day Range:
$250.91
$257.65
1-Week Range:
$243.18
$263.75
52-Week Range:
$122.80
$298.30
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
254.95 | 7.22B | 389.13M | 204.83M | 188.91M | 6.8443 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Fed Watch: Is Krystal Biotech Inc impacted by rising rates2026 EndofMonth & Verified Swing Trading Watchlist - baoquankhu1.vn
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $325 - Moomoo
Published on: 2026-03-23 18:50:19 - baoquankhu1.vn
Why is Krystal Biotech (KRYS) down 11.5% since last earnings report? - MSN
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - MSN
KRYS SEC FilingsKrystal Biotech 10-K, 10-Q, 8-K Forms - Stock Titan
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch - The Globe and Mail
Krystal Biotech Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance - Markets Mojo
(KRYS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
A Look At Krystal Biotech (KRYS) Valuation After Updated Vyjuvek Label And Pipeline Momentum - simplywall.st
Why has Krystal Biotech (KRYS) dropped 11.5% following its most recent earnings announcement? - Bitget
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report? - Yahoo Finance
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 - AOL.com
Quarterly Trades: Is Krystal Biotech Inc impacted by rising ratesMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Vyjuvek Label Update And KB803 Progress Reshape Krystal Biotech Story - simplywall.st
Is It Too Late To Consider Krystal Biotech (KRYS) After Strong Multi‑Year Share Gains? - Yahoo Finance
Guidance Update: Can Krystal Biotech Inc weather a recession2026 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
Updated YJUVEK Label and KB803 Progress Could Be A Game Changer For Krystal Biotech (KRYS) - Yahoo Finance
Whale Trades: Can Krystal Biotech Inc weather a recessionWeekly Stock Recap & Verified Chart Pattern Signals - baoquankhu1.vn
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment - The Motley Fool
Decheng Capital LLC Sells 33,700 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Braidwell LP Cuts Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Avoro Capital Advisors LLC Purchases 117,777 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech Stock Surges on Q4 Beat, But Valuation Questions Linger After CEO Share Sale - AD HOC NEWS
Assessing Krystal Biotech (KRYS) Valuation After Q4 2025 Beat And CEO Stock Sale - simplywall.st
First Trust Advisors LP Has $43.85 Million Stake in Krystal Biotech, Inc. $KRYS - MarketBeat
Capital World Investors Cuts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
8,212 Shares in Krystal Biotech, Inc. $KRYS Bought by WINTON GROUP Ltd - MarketBeat
The Bull Case For Krystal Biotech (KRYS) Could Change Following Q4 Beat And CEO Stock Sales - Sahm
Krystal Biotech Insider Sold Shares Worth $6,580,270, According to a Recent SEC Filing - marketscreener.com
(KRYS) Risk Channels and Responsive Allocation - Stock Traders Daily
Krystal Biotech, Inc. $KRYS Position Trimmed by GW&K Investment Management LLC - MarketBeat
Krishnan Krish S, president of Krystal Biotech, sells $6.58 million in KRYS stock - Investing.com
Krystal Biotech (NASDAQ:KRYS) Insider Sells $6,580,250.00 in Stock - MarketBeat
Krystal Biotech director Krishnan sells $6.58 million in shares By Investing.com - Investing.com Nigeria
Krystal Biotech director Krishnan sells $6.58 million in shares - Investing.com
Krystal Biotech (KRYS) R&D president sells 25,000 shares under 10b5-1 plan - Stock Titan
[Form 4] Krystal Biotech, Inc. Insider Trading Activity - Stock Titan
KRYS Earnings History & Surprises | EPS & Revenue Results | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
[144] Krystal Biotech, Inc. SEC Filing - Stock Titan
Segall Bryant & Hamill LLC Lowers Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Kathryn Romano Sells 750 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Daniel Janney Sells 11,803 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million By Investing.com - Investing.com Canada
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million - Investing.com
Krystal Biotech (KRYS) CAO sells shares and receives fresh stock awards - Stock Titan
Krystal Biotech (KRYS) R&D chief logs new awards, PSU vesting and tax trades - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO reports new equity awards and tax share surrenders - Stock Titan
Alta Bioequities linked to Krystal Biotech (KRYS) director sells 11,803 shares - Stock Titan
Krystal Biotech, Inc. $KRYS Position Increased by William Blair Investment Management LLC - MarketBeat
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):